References
- Raghu G, Remy-Jardin M, Myers JL, et al. American thoracic society, European respiratory society, Japanese respiratory society, and Latin American thoracic society. diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
- Maria -M-M, Molina-Molina M. Interstitial lung diseases in developing countries. Ann Glob Health. 2019;85(1):4.
- King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5(1):72–84.
- Cottin V, Nunes H, and Brillet PY, et al. Groupe d’Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593.
- Mitchell PD, Das JP, Murphy DJ, et al. Idiopathic pulmonary fibrosis with emphysema: evidence of synergy among emphysema and idiopathic pulmonary fibrosis in smokers. Respir Care. 2015;60(2):259–268.
- Ciccarese F, Attinà D, and Zompatori M. Combined pulmonary fibrosis and emphysema (CPFE): what radiologist should know. Radiol Med. 2016;121(7):564–572.
- Vincent C. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev. 2013;22(128):153–157.
- Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136(1):10–15.
- Yoon HY, Kim TH, and Seo JB, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology. 2019;24(1):55–62.
- Kurashima K, Takayanagi N, Tsuchiya N, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology. 2010;15(5):843–848.
- Bodlet A, Maury G, Jamart J, et al. Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis. Respir Med. 2013;107(11):1781–1788.
- DA L, Sverzellati N, Wd T, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper. Lancet Respir Med. 2018;6(2):138–153.
- Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–969.
- Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691.
- Yan W, Peng LY, Ban CJ, et al. Incidence and clinical characteristics of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chin Med J (Engl). 2015;128(7):896–901.
- Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177(2):190–194.
- Shin KE, Chung MJ, Jung MP, et al. Quantitative computed tomographic indexes in diffuse interstitial lung disease: correlation with physiologic tests and computed tomography visual scores. J Comput Assist Tomogr. 2011;35(2):266–271.
- Matsuoka S, Yamashiro T, and Matsushita S, et al. Quantitative CT evaluation in patients with combined pulmonary fibrosis and emphysema: correlation with pulmonary function. Acad Radiol. 2015;22(5):626–631.
- Ye Q, Huang K, Ding Y, et al. Cigarette smoking contributes to idiopathic pulmonary fibrosis associated with emphysema. Chin Med J (Engl). 2014;127(3):469–474.
- Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology. 2014;19(2):239–245.
- Nakazawa S, Shimizu K, Mogi A, et al. Low diffusing capacity, emphysema, or pulmonary fibrosis: who is truly pulling the lung cancer strings? J Thorac Dis. 2018;10(2):600–602.
- Hadjiliadis D, Tapson VF, Davis RD, et al. Prognostic value of serum carcinoembryonic antigen levels in patients who undergo lung transplantation. J Heart Lung Transplant. 2001;20(12):1305–1309.
- Fahim A, Crooks MG, Wilmot R, et al. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis. Respirology. 2012;17(8):1247–1252.
- Xu L, Bian W, Gu XH, et al. Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. Copd. 2017;14(2):245–250.
- d’Alessandro M, Bergantini L, Torricelli E, et al. Systematic review and metanalysis of oncomarkers in IPF patients and serial changes of oncomarkers in a prospective Italian real-life case series. Cancers (Basel). 2021;13(3):539.
- Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5(12):946–955.
- Dai H, Liu J, Liang L, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology. 2014;19(5):707–713.
- Çiftci F, Gülpınar B, and Atasoy Ç, et al. Combined pulmonary fibrosis and emphysema: how does cohabitation affect respiratory functions? Adv Med Sci. 2019;64(2):285–291.
- Costa CM, Neder JA, Verrastro CG, et al. Uncovering the mechanisms of exertional dyspnoea in combined pulmonary fibrosis and emphysema. Eur Respir J. 2020;55(1):1901319.
- Suzuki M, Kawata N, and Abe M, et al. Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: relationship with pulmonary function and clinical events. PLoS One. 2020;15(9):e0239066.
- Brillet P, Cottin V, and Letoumelin P, et al. Syndrome emphysème des sommets et fibrose pulmonaire des bases combinés (syndrome emphysème/fibrose): aspects tomodensitométriques et fonctionnels [Combined apical emphysema and basal fibrosis syndrome (emphysema/fibrosis syndrome): CT imaging features and pulmonary function tests]. J Radiol. 2009;90(1 Pt 1):43–51.
- Jacob J, Bartholmai BJ, Rajagopalan S, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(1):1700379.
- Kohashi Y, Arai T, Sugimoto C, et al. Clinical impact of emphysema evaluated by high-resolution computed tomography on idiopathic pulmonary fibrosis diagnosed by surgical lung biopsy. Respiration. 2016;92(4):220–228.
- Akyıl F T, Sevim T, Akman C, et al. The predictors of mortality in IPF does emphysema change the prognosis? Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):267–274.
- Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
- Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.
- Zurkova M, Kriegova E, Kolek V, et al. IPF registry. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respir Res. 2019;20(1):16.
- Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–79.
- Cottin V, Le Pavec J, Prévot G, et al., GERM”O”P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105–111.